FATE

Fate Therapeutics Stock Price

82.42
-3.77 (-4.37%)
Upgrade to Real-Time
Regular Market
82.42

Low
29.37

52 Week Range

High
121.16

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Fate Therapeutics Inc FATE NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-3.77 -4.37% 82.42 13:46:21
Open Price Low Price High Price Close Price Prev Close
86.01 81.575 86.93 86.19
Bid Price Ask Price Spread News
82.27 82.54 0.27 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,304 299,790 $ 83.89 $ 25,149,198 - 29.37 - 121.16
Last Trade Time Type Quantity Stock Price Currency
13:46:10 1 $ 82.5399 USD

Period:

Draw Mode:

Fate Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 7.75B 94.04M 66.90M $ 31.43M $ - -2.08 -40.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 6.36k 1.30%

more financials information »

Fate Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical FATE Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week76.8487.1876.0084.36786,3895.587.26%
1 Month87.5095.3873.8485.83880,593-5.08-5.81%
3 Months89.8495.3865.1380.74988,587-7.42-8.26%
6 Months96.74118.1465.1385.05979,808-14.32-14.8%
1 Year32.00121.1629.3774.54980,20650.42157.56%
3 Years9.19121.168.6440.71874,35773.23796.84%
5 Years1.70121.161.6733.09679,80080.724,748.24%

Fate Therapeutics Description

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.


Your Recent History
NASDAQ
FATE
Fate Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.